Current Report Filing (8-k)
November 15 2016 - 5:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
November
4, 2016
Date
of Report (Date of earliest event reported)
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.
|
37
North Orange Ave, Suite 607, Orlando, FL
|
|
32801
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01 Other Events
On
November 4, 2016, Immune Therapeutics, Inc. (the “Company”) paid off its Promissory Note with JMJ Financial, disclosed
in the Current Form 8K/A filed by the Company on May 4, 2016, in the principal amount of $656,250. These funds came from financing
provided by certain of the Company’s current shareholders.
On
November 14, 2016, the Company issued a press release announcing its intent and efforts to restructure approximately $1,700,000
of its current debt.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits. The following exhibits are filed herewith.
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
|
Date:
November 15, 2016
|
By:
|
/s/
Noreen Griffin
|
|
|
Noreen
Griffin, CEO
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Sep 2023 to Sep 2024